Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivation

Junichi Matsuo1, Yoshinori Tsukumo, Sakae Saito

  • 1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

Insights

Biguanides like metformin selectively kill glucose-deprived cancer cells by hyperactivating eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), inhibiting cell survival pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Stress Response

Background:

  • Biguanides (metformin, buformin, phenformin) show potential as antitumor agents.
  • These drugs induce cell death under glucose deprivation, a condition prevalent in tumors.
  • Glucose deprivation is a critical factor in the tumor microenvironment influencing treatment efficacy.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which biguanides induce cell death in glucose-deprived cancer cells.
  • To investigate the role of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) in biguanide-mediated cell death.
  • To explore the connection between 4E-BP1, the unfolded protein response (UPR), and the mTOR signaling pathway in cancer therapy.

Main Methods:

  • Cellular assays to assess biguanide effects on glucose-deprived cells.
  • Western blotting and molecular analysis to evaluate protein activation and signaling pathways (4E-BP1, UPR, mTOR).
  • In vivo studies using xenografted cancer models treated with biguanides.

Main Results:

  • Biguanide treatment leads to hyperactivation of 4E-binding protein 1 (4E-BP1) in glucose-deprived cells.
  • Hyperactivated 4E-BP1 inhibits the unfolded protein response (UPR), a key cell survival pathway.
  • This inhibition of UPR is mediated by the suppression of the mTOR signaling pathway.
  • Biguanide-induced 4E-BP1 hyperactivation and subsequent UPR inhibition were confirmed in vivo.

Conclusions:

  • Antitumor effects of biguanides are linked to 4E-BP1 hyperactivation.
  • This mechanism selectively eliminates glucose-deprived cancer cells by disrupting UPR.
  • Targeting the 4E-BP1/UPR/mTOR axis offers a potential therapeutic strategy for cancers experiencing glucose deprivation.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...